Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EBITDA (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed EBITDA for 6 consecutive years, with -$12.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 119.11% to -$12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$51.1 million, a 154.82% decrease, with the full-year FY2024 number at -$28.6 million, down 42.31% from a year prior.
  • EBITDA was -$12.8 million for Q3 2025 at Inhibikase Therapeutics, down from -$10.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.6 million in Q1 2021 to a low of -$14.6 million in Q1 2025.
  • A 5-year average of -$6.3 million and a median of -$4.7 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 573.64% in 2021, then grew 18.57% in 2024.
  • Inhibikase Therapeutics' EBITDA stood at -$5.0 million in 2021, then rose by 14.01% to -$4.3 million in 2022, then decreased by 1.58% to -$4.4 million in 2023, then tumbled by 193.6% to -$12.9 million in 2024, then increased by 1.24% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's EBITDA are -$12.8 million (Q3 2025), -$10.8 million (Q2 2025), and -$14.6 million (Q1 2025).